We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs


The Supreme Court of Canada grants leave to appeal in the Plavix case
  • Bereskin & Parr LLP
  • Canada
  • January 30 2014

The Supreme Court of Canada announced today that it has granted leave to appeal to Apotex Inc. from the Federal Court of Appeal (FCA) in the patent


Supreme Court amends earlier decision: Viagra patent not void
  • Bereskin & Parr LLP
  • Canada
  • June 6 2013

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Subsequent entry biologics in Canada: competition vs. exclusivities
  • Bereskin & Parr LLP
  • Canada
  • February 13 2012

Canada has approved the subsequent entry biologic (SEB), Omnitrope (somatropin), following in the footsteps of the U.S. and European approvals


Billion dollar drug litigation opens a front in Canada
  • Bereskin & Parr LLP
  • Canada
  • June 6 2012

Amgen recently started litigation against Teva over the biologic drug filgrastim (Court File No. T-989-12